Gylden Pharma
Developer of synthetic T cell‑priming vaccine and immunotherapy candidates. Focus areas include discovery and selection of MHC class I peptides (ligandome libraries), development of multi‑epitope synthetic T cell vaccines, and delivery system development (nanoparticles and microneedle platforms). Pipeline indications include betacoronaviruses, dengue, universal/pandemic influenza, chikungunya and other intracellular pathogens. The company collaborates with academic research institutes and participates in early‑phase clinical studies.
Industries
Nr. of Employees
small (1-50)
Gylden Pharma
Abingdon, Oxfordshire, United Kingdom, Europe
Products
Pipeline of T cell‑priming vaccine candidates
A pipeline of synthetic T cell‑priming vaccine and immunotherapy candidates targeting betacoronaviruses, dengue, universal/pandemic influenza, chikungunya and intracellular bacterial pathogens.
Pipeline of T cell‑priming vaccine candidates
A pipeline of synthetic T cell‑priming vaccine and immunotherapy candidates targeting betacoronaviruses, dengue, universal/pandemic influenza, chikungunya and intracellular bacterial pathogens.
Services
Vaccine candidate discovery and preclinical development
Identification and preclinical evaluation of conserved peptide antigens and multi‑epitope vaccine constructs using immunopeptidomics and proteomics.
Vaccine delivery system development
Development of nanoparticle formulations and microneedle delivery approaches for administration of synthetic peptide vaccines.
Clinical development and operations for early phase trials
Management and operational support for Phase I clinical studies including clinical operations leadership.
Vaccine candidate discovery and preclinical development
Identification and preclinical evaluation of conserved peptide antigens and multi‑epitope vaccine constructs using immunopeptidomics and proteomics.
Vaccine delivery system development
Development of nanoparticle formulations and microneedle delivery approaches for administration of synthetic peptide vaccines.
Clinical development and operations for early phase trials
Management and operational support for Phase I clinical studies including clinical operations leadership.
Expertise Areas
- T‑cell priming vaccine development
- Immunopeptidomics and antigen discovery
- Proteomics and targeted mass spectrometry
- Nanoparticle and microneedle vaccine delivery
Key Technologies
- MHC class I peptide libraries / ligandome screening
- Immunopeptidomics
- Targeted mass spectrometry
- Label‑free quantitative proteomics